"AIDS Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.
| Descriptor ID |
D016915
|
| MeSH Number(s) |
D20.215.894.899.050
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "AIDS Vaccines".
Below are MeSH descriptors whose meaning is more specific than "AIDS Vaccines".
This graph shows the total number of publications written about "AIDS Vaccines" by people in this website by year, and whether "AIDS Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 2 | 1 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 0 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 0 | 3 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 6 | 2 | 8 |
| 2015 | 4 | 4 | 8 |
| 2016 | 6 | 3 | 9 |
| 2017 | 3 | 1 | 4 |
| 2018 | 4 | 4 | 8 |
| 2019 | 7 | 0 | 7 |
| 2020 | 8 | 0 | 8 |
| 2021 | 11 | 0 | 11 |
| 2022 | 7 | 0 | 7 |
| 2023 | 3 | 0 | 3 |
| 2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "AIDS Vaccines" by people in Profiles.
-
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. J Infect Dis. 2024 Aug 16; 230(2):e405-e415.
-
Evaluating the antibody response elicited by diverse HIV envelope immunogens in the African green monkey (Vervet) model. Sci Rep. 2024 06 10; 14(1):13311.
-
Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702. Vaccine. 2024 Aug 13; 42(20):125991.
-
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. PLoS Med. 2024 Mar; 21(3):e1004360.
-
Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines. J Virol. 2024 Jan 23; 98(1):e0147823.
-
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. EBioMedicine. 2023 Jul; 93:104590.
-
Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa. AIDS Behav. 2023 Sep; 27(9):3027-3037.
-
Exploring a community's understanding of HIV vaccine-induced seropositivity in a South African research setting. S Afr Med J. 2022 12 20; 113(1):36-41.
-
A qualitative study of stakeholder and researcher perspectives of community engagement practices for HIV vaccine clinical trials in South Africa. J Community Psychol. 2023 04; 51(3):998-1015.
-
Use of Varied Screening Risk Criteria and HIV Incidence in Phase 1 and 2 HIV Vaccine Trials in South Africa. AIDS Behav. 2023 Apr; 27(4):1314-1320.